Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2022

View Archived Issues

BLU-945 for treatment-resistant EGFR T790M mutation-driven lung cancer

Medshine Discovery divulges thyroid hormone receptor beta agonists

Galderma discovers JAK-1 inhibitors

New NFE2-related factor 2 activators described by Sanofi

CNRS and collaborators patent acetylcholinesterase reactivators

RemeGen discloses new anti-c-Met antibody-drug conjugates

Telomere to telomere, the human genome is done

Novel humanized HIS-BRGS mouse model to evaluate immune-related kidney toxicities

New orthotopic xenograft breast cancer murine models developed

Humanized mouse model to asses acute toxicity of immune drug treatments

Sosei Heptares presents novel GLP-1 receptor antagonist HTL-0033097

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...